PRESS RELEASE published on 02/25/2026 at 06:45, 6 months 14 days ago #FutureFresenius: REJUVENATE in action – Delivering accelerated performance for long-term value creation; 2025 yet another year of strong delivery Fresenius SE & Co. KGaA reports strong FY/25 results with 7% organic revenue growth and 12% Core EPS growth. Improved EBIT margin and increased dividend proposal. #FutureFresenius strategy aims for sustainable growth Financial Results Organic Revenue Growth Fresenius Core EPS #FutureFresenius
PRESS RELEASE published on 02/25/2026 at 06:30, 6 months 14 days ago Formycon announces positive clinical data for Keytruda® biosimilar candidate FYB206 (pembrolizumab) Formycon announces positive clinical data for Keytruda biosimilar candidate FYB206 (pembrolizumab), confirming pharmacokinetic equivalence with Keytruda Clinical Data Biosimilar Formycon Keytruda Pembrolizumab
PRESS RELEASE published on 02/25/2026 at 06:00, 6 months 14 days ago Fresenius Supervisory Board extends ahead of schedule CEO Michael Sen’s contract by five years --- Christian Pawlu to join Management Board for Fresenius Helios effective July 1, 2026 Fresenius extends CEO Michael Sen's contract by 5 years and appoints Christian Pawlu to Management Board effective July 1, 2026, ensuring continuity and strategic leadership for #FutureFresenius. Dr. Pawlu to oversee Fresenius Helios operations replacing Robert Möller Contract Extension Management Board CEO Fresenius Christian Pawlu
PRESS RELEASE published on 02/25/2026 at 01:10, 6 months 14 days ago Northfield Announces Intention to Commence Normal Course Issuer Bid Northfield Capital Corporation announces normal course issuer bid to purchase up to 1,035,239 Class A restricted voting shares on TSXV. The bid aims to capitalize on undervalued shares TSX Venture Exchange Normal Course Issuer Bid Class A Shares Undervalued Northfield Capital Corporation
PRESS RELEASE published on 02/25/2026 at 00:50, 6 months 14 days ago Pew Applauds Milestone Ratification of International Treaty to Improve Safety at Sea The Pew Charitable Trusts welcomes the ratification of the Cape Town Agreement to enhance safety at sea, protect fishers, and combat IUU fishing, marking a significant step towards sustainable ocean governance IUU Fishing Cape Town Agreement Pew Charitable Trusts Safety At Sea Sustainable Ocean Governance
PRESS RELEASE published on 02/25/2026 at 00:00, 6 months 14 days ago Nepra Foods Announces Closing of Debt Conversion Nepra Foods Inc. announces debt conversion transaction with Lender William Hogan, issues Common Shares. Shares subject to statutory hold period. Details on US securities laws compliance provided Common Shares Nepra Foods Inc. Debt Conversion Transaction Statutory Hold Period US Securities Laws
PRESS RELEASE published on 02/24/2026 at 22:45, 6 months 14 days ago 2CRSi SA: Après la qualification réussie du fluide, Chemours et 2CRSi s’associent pour accélérer l’adoption du refroidissement liquide biphasé dans les serveurs haute densité. Chemours et 2CRSi s'associent pour accélérer l'adoption du refroidissement liquide biphasé dans les serveurs haute densité et les infrastructures informatiques Innovation Technologique 2CRSi Serveurs Haute Densité Chemours Refroidissement Liquide Biphasé
PRESS RELEASE published on 02/24/2026 at 22:45, 6 months 14 days ago 2CRSi SA: Following Successful Fluid Qualification Chemours & 2CRSi Join Forces to Accelerate Deployment of Two-Phase Liquid Cooling for High-Density Servers. Chemours and 2CRSi collaborate on high-density server cooling solutions using Opteon fluid, aiming to drive innovation and energy efficiency in data centers Energy Efficiency 2CRSi Data Centers Chemours Server Cooling
PRESS RELEASE published on 02/24/2026 at 22:45, 6 months 14 days ago 2CRSi SA: Following Successful Fluid Qualification Chemours & 2CRSi Join Forces to Accelerate Deployment of Two-Phase Liquid Cooling for High-Density Servers. Chemours and 2CRSi announce Joint Development Agreement to accelerate deployment of Two-Phase Liquid Cooling for high-density servers & IT equipment. Partnership aims to drive innovation and energy efficiency 2CRSi Joint Development Agreement High-density Servers Chemours Two-Phase Liquid Cooling
PRESS RELEASE published on 02/24/2026 at 22:45, 6 months 14 days ago 2CRSi SA: Après la qualification réussie du fluide, Chemours et 2CRSi s’associent pour accélérer l’adoption du refroidissement liquide biphasé dans les serveurs haute densité. Chemours et 2CRSi s'associent pour accélérer l'adoption du refroidissement liquide biphasé dans les serveurs haute densité. Accord de développement conjoint pour l'innovation technologique 2CRSi Accord De Développement Serveurs Haute Densité Chemours Refroidissement Liquide Biphasé
Published on 09/11/2026 at 04:00, 5 hours 11 minutes ago Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 10 hours 46 minutes ago Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 15:20, 17 hours 51 minutes ago MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 18 hours 11 minutes ago All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Published on 09/11/2026 at 09:05, 5 minutes ago ROHM's New High Anti-surge Chip Resistors in "SDR01 Series" Achieve 0.33W Rated Power in 0402 Size
Published on 09/11/2026 at 09:00, 11 minutes ago Homann Holzwerkstoffe publishes its 2026 half-year report
Published on 09/11/2026 at 09:00, 11 minutes ago Mountain Alliance AG invests in Evolved Aerospace and expands its involvement in the European defence technology market
Published on 09/11/2026 at 07:00, 2 hours 11 minutes ago Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 2 hours 11 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 2 hours 11 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 13 hours 41 minutes ago Availability of the 2026 Interim Financial Report